CN103142638A - Pharmaceutical composition for treating gastric ulcer - Google Patents
Pharmaceutical composition for treating gastric ulcer Download PDFInfo
- Publication number
- CN103142638A CN103142638A CN201310093317XA CN201310093317A CN103142638A CN 103142638 A CN103142638 A CN 103142638A CN 201310093317X A CN201310093317X A CN 201310093317XA CN 201310093317 A CN201310093317 A CN 201310093317A CN 103142638 A CN103142638 A CN 103142638A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- omeprazole
- gastric
- ulcer
- colloidal bismmth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a pharmaceutical composition for treating gastric ulcer. The pharmaceutical composition comprises colloidal bismuth pectin and omeprazole, wherein colloidal bismuth pectin and omeprazole have synergistic treatment effects.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, specifically a kind of pharmaceutical composition for the treatment of gastric ulcer.
Background technology
The medicine for the treatment of in the market gastric ulcer has a variety of, and as bismuth potassium citrate, SANJIU WEITAI etc., but expensive, therapeutic effect is not fully up to expectations.These medicines can only relief of symptoms, and the time has been grown and will have a relapse, and even causes other diseases.
Colloidal bismmth pectin is a kind of novel macromolecule bismuth, and molecular weight is large, and is colloid-stabilised, be difficult to be absorbed by the body, and the untoward reaction and the side effect that easily cause without similar drugs.Be mainly used in treating chronic gastritis.Colloidal bismmth pectin with the biomacromolecule pectic acid replaced in traditional bismuth preparation in, the micromolecule acid group, improved colloid property, mucosa is stronger; Observe under gastroscope, the colloidal bismmth pectin gel more trends towards being deposited on ulcer and hemorrhage mucomembranous surface, has fabulous selection adhesiveness.Colloidal bismmth pectin is mainly used in gastric and duodenal ulcers, also can be used for the treatment of chronic superficial gastritis, chronic atrophic gastritis and digestive tract hemorrhage.
Omeprazole, the another name losec is a kind of proton pump inhibitor of secretion of gastric acid inhibitory effectively.Optionally act on the gastric mucosa parietal cell, suppress to be in secreted microtubule that parietal cell top film consists of and the activity of the H+-K+-ATP enzyme on intracytoplasmic tubular foam, thereby the secretion of gastric acid inhibitory effectively, onset is rapid, be applicable to gastric and duodenal ulcers, reflux esophagitis and gastrinoma.Because H+, K+-ATP enzyme are last processes that parietal cell secretes acid, therefore that this product presses down sour ability is powerful, the effect of the gastric acid secretion due to strong and lasting inhibition basis gastric acid and food, pentapeptide gastric acid secretin is arranged.It can not only suppress the gastric acid secretion that gastrin, histamine, choline and food, vagus nerve stimulation etc. cause by noncompetitive, and can suppress the part basal gastric acid secretion that not affected by choline or H2 receptor blocking agent, stimulate the gastric acid secretion that causes that strong and lasting inhibitory action is also arranged to bisfentidine is untamed by dibutyl cyclic adenosine monophosphate (DcAMP).Produce effects is fast, and is reversible, and brings out the side effect of spiritual aspect without bisfentidine.This product also has inhibitory action to pepsinia, and is not obvious to the change of Gastric Mucosa Blood Flow amount, also do not affect body temperature, gastral cavity temperature, arteriotony, venous blood Lactoferrin, art pO2, partial pressure of carbon dioxide and arterial blood ph.The effect of the gastric acid secretion due to strong and lasting inhibition basis gastric acid and food, pentapeptide gastric acid secretin is arranged.Produce effects is fast, and is reversible, and brings out the side effect of spiritual aspect without bisfentidine.Be used for gastric and duodenal ulcers, anti-fluidity or erosive esophagitis, ZE syndrome etc., to also effective with the invalid gastric duodenal ulcer of bisfentidine.Be used for gastric and duodenal ulcers, anti-fluidity or erosive esophagitis, ZE syndrome etc., to also effective with the invalid gastric duodenal ulcer of bisfentidine.
Summary of the invention
The applicant is surprised to find that the pharmaceutical composition of colloidal bismmth pectin and omeprazole has synergy for the treatment gastric ulcer.
The purpose of this invention is to provide a kind of pharmaceutical composition for the treatment of gastric ulcer, comprising colloidal bismmth pectin and omeprazole.
According to the pharmacological experiment data, the compositions of colloidal bismmth pectin and omeprazole for the treatment gastric ulcer have synergism, combined effect both be better than far away alone one of them.
The invention provides a kind of pharmaceutical composition, comprising colloidal bismmth pectin or omeprazole.
The present invention also provides a kind of pharmaceutical composition, wherein is comprised of colloidal bismmth pectin and omeprazole.
The present invention also provides a kind of pharmaceutical composition, wherein also comprises the acceptable adjuvant of pharmacy and excipient.
The present invention also provides a kind of preparation method of pharmaceutical composition, and wherein active component is colloidal bismmth pectin and omeprazole, makes the acceptable dosage form of pharmacy according to the conventional preparation method of pharmaceutical field and gets final product.
According to the embodiment of the present invention, comprising:
A kind of pharmaceutical composition is comprising appropriate colloidal bismmth pectin or omeprazole.
A kind of pharmaceutical composition wherein is comprised of colloidal bismmth pectin and omeprazole, and part by weight both is 20-80%:80-20%.
Pharmaceutical composition of the present invention can be prepared into the acceptable dosage form of pharmacy.
The acceptable adjuvant of pharmacy of the present invention and excipient comprise filler, lubricant, disintegrating agent, fluidizer etc.
Preparation method comprises supplementary material pulverized and sieved, and gets appropriate active component and adjuvant or mixed with excipients even, and the punch die tabletting checks that packing gets final product.
Embodiment
Embodiment 1
60mg colloidal bismmth pectin and the 40mg omeprazole part by weight according to 60%:40% is mixed, be prepared into pharmaceutical composition.
Embodiment 2
20mg colloidal bismmth pectin and the 80mg omeprazole part by weight according to 20%:80% is mixed, be prepared into pharmaceutical composition.
Embodiment 3
50mg colloidal bismmth pectin and the 50mg omeprazole part by weight according to 50%:50% is mixed, be prepared into pharmaceutical composition.
The pharmaceutically active test
By treatment and the observation to clinical patients w ith peptic ulcer disease, the average cure rate of pharmaceutical composition of the present invention is 98.1%, far away higher than using separately wherein a kind of medicine.Concrete data see Table 1.
Experimental group is above-described embodiment 1-3 medicine, and matched group 1 is the 100mg colloidal bismmth pectin, and matched group 2 is the 100mg omeprazole, and matched group 3 is the 100mg bismuth potassium citrate.30 days is a course for the treatment of.
Table 1
| Group | Patient's number | The healing number | Cure rate |
| Embodiment 1 | 90 | 88 | 97.8% |
[0029]?
| Embodiment 2 | 90 | 89 | 98.9% |
| Embodiment 3 | 87 | 85 | 97.7% |
| Matched group 1 | 90 | 28 | 31.1% |
| Matched group 2 | 87 | 25 | 28.7% |
| Matched group 3 | 90 | 19 | 21.1% |
The pharmaceutical composition of table 1 data show colloidal bismmth pectin of the present invention and omeprazole has obvious synergistic therapeutic action.The patient that in experimentation, embodiment 1-3 treats has 8 routine DeGrains, mainly due to patient's heavy drinking or overworked due to.Course for the treatment of of continual cure, substantially can both fully recover.
Colloidal bismmth pectin and the Mus pyloric ligation ulcers acute gastric ulcer effect experiment of omeprazole Chinese People's Anti-Japanese Military and Political College
1.1 test method: Wister rat, body weight 250g ± 30g, male and female half and half.Animal is divided into 3 experimental grouies (embodiment 1-3) at random, 3 matched groups (matched group 1 is the 100mg colloidal bismmth pectin, and matched group 2 is the 100mg omeprazole, and matched group 3 is the 100mg bismuth potassium citrate) and 1 blank group.Above medicine all is made into desired concn with 5g/L carboxymethyl cellulose (carboxymethyl cellulose, CMC) solution with front.The normal saline of blank group ig respective volume.The above-mentioned gavage 1 time every day of respectively organizing by measure, 15d continuously, each group is all supplied with normal diet.Each organizes fasting 48h after the last administration, uses pylorus ligature law, makes gastric ulcer model.Concrete operations are: under rat general anesthesia state, the sterile working opens the abdominal cavity along ventrimeson, and the ligation pylorus is sewed up stomach wall, and postoperative is with the animal sub-cage rearing.Sacrificed by decapitation animal after 19h is then with the fixing stomach specimen of 1% formalin.Cut open inspection after 30min, calculate ulcer index.
1.2 date processing: data are with (x ± SD) the expression of mean ± standard deviation.According to every group of ulcer index of gained, the computing formula of pressing ulcer inhibition rate: ulcer inhibition rate=[(matched group index-administration class index)/matched group index] * 100%; Calculate ulcer inhibition rate.The relatively employing t check of each group difference.
2. result
Find to occur in the blank group gastric ulcer perforation after dissecting, other each groups have no perforation, and ig embodiment 1-3 pharmaceutical composition can obviously suppress the formation (table 2) of rat pyloric ligation ulcers acute gastric ulcer.
The impact on rat pyloric ligation ulcers acute gastric ulcer of table 2ig colloidal bismmth pectin and omeprazole
Compare with the blank group: P＜0.01.
Claims (3)
1. pharmaceutical composition is comprising colloidal bismmth pectin or omeprazole.
2. a pharmaceutical composition, wherein be comprised of colloidal bismmth pectin and omeprazole.
3. pharmaceutical composition as claimed in claim 2, the part by weight of colloidal bismmth pectin and omeprazole is 20-80%:80-20%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310093317XA CN103142638A (en) | 2013-03-21 | 2013-03-21 | Pharmaceutical composition for treating gastric ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310093317XA CN103142638A (en) | 2013-03-21 | 2013-03-21 | Pharmaceutical composition for treating gastric ulcer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103142638A true CN103142638A (en) | 2013-06-12 |
Family
ID=48541147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310093317XA Pending CN103142638A (en) | 2013-03-21 | 2013-03-21 | Pharmaceutical composition for treating gastric ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103142638A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104771757A (en) * | 2015-02-04 | 2015-07-15 | 沈阳伟嘉牧业技术有限公司 | Compound preparation for treating broiler proventriculitis |
| CN106727551A (en) * | 2016-12-27 | 2017-05-31 | 郑州莉迪亚医药科技有限公司 | It is a kind of to treat Western medicine compound of gastric ulcer and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634132A (en) * | 2003-12-29 | 2005-07-06 | 湖南华纳大药厂有限公司 | Dispersible tablet of colloid petcin |
| CN101015694A (en) * | 2006-02-07 | 2007-08-15 | 沈阳东宇药业有限公司 | Compound oral preparation for treating spirobacillus infection of pylorus |
-
2013
- 2013-03-21 CN CN201310093317XA patent/CN103142638A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634132A (en) * | 2003-12-29 | 2005-07-06 | 湖南华纳大药厂有限公司 | Dispersible tablet of colloid petcin |
| CN101015694A (en) * | 2006-02-07 | 2007-08-15 | 沈阳东宇药业有限公司 | Compound oral preparation for treating spirobacillus infection of pylorus |
Non-Patent Citations (5)
| Title |
|---|
| 冯雪芹 等: "《胶体果胶铋联合奥美拉唑治疗反流性食管炎的临床观察》", 《中国实用医药》 * |
| 徐二琴1 ,李大鹏2: "《奥美拉唑与胶体果胶铋联用治疗消化性溃疡40 例》", 《蚌埠医学院学报》 * |
| 曹恩东: "《消化性溃疡的临床治疗》", 《中国当代医药》 * |
| 秦宏伟: "《消化性溃疡270例临床治疗分析》", 《求医问药》 * |
| 陈 泉: "《86例消化性溃疡临床治疗分析》", 《中国医药指南》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104771757A (en) * | 2015-02-04 | 2015-07-15 | 沈阳伟嘉牧业技术有限公司 | Compound preparation for treating broiler proventriculitis |
| CN106727551A (en) * | 2016-12-27 | 2017-05-31 | 郑州莉迪亚医药科技有限公司 | It is a kind of to treat Western medicine compound of gastric ulcer and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102397524A (en) | Composition for protecting gastric mucosa, nourishing stomach and protecting stomach and preparation method thereof | |
| WO2019087100A1 (en) | Suckable and/or melt-in-mouth tablet based on hyaluronic acid and chondroitin sulphate and salts thereof for use in the treatment of a subpopulation of gerd patients | |
| CN103142638A (en) | Pharmaceutical composition for treating gastric ulcer | |
| CN100594911C (en) | Medicine composition and use | |
| CN102210685A (en) | Application of ectoine and derivatives thereof in preparing medicament for preventing and treating digestive tract diseases caused by chemotherapy medicaments | |
| CN106511394B (en) | Application of aspongopus fatty oil extract | |
| EP3244885B1 (en) | Lipoic acid for treating or preventing threatened miscarriage or preterm delivery | |
| WO2008001360A2 (en) | Compositions and methods for treating and preventing gastro esophageal reflux disease | |
| CN104116732B (en) | A kind of application of andrographolide | |
| CN104027344A (en) | Lincomycin-containing drug composition | |
| CN103156880B (en) | Pharmaceutical composite containing colloidal bismuth pectin | |
| CN108992549A (en) | A kind of pharmaceutical composition and preparation method thereof, application | |
| CN103735693B (en) | One treats the dyspeptic Chinese medicine preparation of caused by hepatic stagnation qi stagnation | |
| CN113350333B (en) | EGCG (epigallocatechin gallate) combined medicine and medical application thereof | |
| CN116983314B (en) | Application of D1-like receptor agonist in preparation of gastric motility enhancing drugs | |
| CN103142672B (en) | Pharmaceutical composition | |
| CN103908448A (en) | New application of rabeprazole in pharmacy | |
| TWI794847B (en) | Composition for reducing metabolic syndrome and application thereof | |
| Surana et al. | Evaluation of adjunctive analgesia with intrathecal fentanyl along with hyperbaric bupivacaine in spinal anesthesia for elective cesarean section | |
| de Souza Hobaika et al. | Late. maternal hypotension after administration of amini-dose of clonidine added to epidural analgesia for la-bor | |
| Sigdel et al. | Comparison of Ondansetron with Gabapentin for prevention of intrathecal morphine induced pruritus | |
| CN103550373B (en) | Medicament for treating gingivitis | |
| CN108743676A (en) | Radix Paeoniae Alba is preparing the application process in treating hypertension drug | |
| CN111840401A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating gastrointestinal hemorrhage | |
| CN102349928A (en) | Combined drug for treating upper gastrointestinal tract ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 266103 Qingdao economic and Technological Development Zone, unity Road, No. 3601, Shandong Applicant after: Qingdao Zhengda Haier Pharmaceutical Co., Ltd. Address before: 266103 Haier Road, Shandong, Qingdao, No. 1 Applicant before: Qingdao Zhengda Haier Pharmaceutical Co., Ltd. |
|
| CB02 | Change of applicant information | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130612 |